Patrick D. Wilkinson, Evan R. Delgado, Frances Alencastro, Madeleine P. Leek, Nairita Roy, Matthew P. Weirich, Elizabeth C. Stahl, P. Anthony Otero, Maelee I. Chen, Whitney K. Brown, Andrew W. Duncan – 23 September 2018 – The liver contains a mixture of hepatocytes with diploid or polyploid (tetraploid, octaploid, etc.) nuclear content. Polyploid hepatocytes are commonly found in adult mammals, representing ~90% of the entire hepatic pool in rodents.

Jesús Quintero, Cristina Molera, Javier Juamperez, Susanna Redecillas, Silvia Meavilla, Raquel Nuñez, Camila García, Mireia del Toro, Ángels Garcia, Juan Ortega, Óscar Segarra, Javier Martin de Carpi, Itxarone Bilbao, Ramon Charco – 22 September 2018 – Despite optimal medical treatment and strict low‐protein diet, the prognosis of propionic acidemia (PA) patients is generally poor. We aim to report our experience with liver transplantation (LT) in the management of PA patients. Six patients with PA received a LT at a mean age of 5.2 years (1.3‐7.5 years).

Jason J. Pan, Fei Bao, Emma Du, Chase Skillin, Catherine T. Frenette, Jill Waalen, Lakshmi Alaparthi, Zachary D. Goodman, Paul J. Pockros – 21 September 2018 – Sustained virologic response (SVR) after direct‐acting antiviral (DAA) therapy for chronic hepatitis C results in significant decreases in liver stiffness measured by transient elastography (TE). The aim of this study was to clarify if TE can guide post‐SVR management in patients with advanced fibrosis or cirrhosis prior to treatment as current guidelines are unclear on the role of TE after SVR.

Jungchan Park, Seung‐Hwa Lee, Jeayoun Kim, Soo Jung Park, Myung Soo Park, Gyu‐Seong Choi, Suk‐Koo Lee, Gaab Soo Kim – 21 September 2018 – We aimed to evaluate the association between intraoperative pulmonary vascular resistance (PVR) and clinical outcome of liver transplantation (LT). Cardiovascular involvement of end‐stage liver disease is relatively common, and hemodynamic instability during LT can be fatal to recipients. However, the clinical impact of intraoperative PVR in LT remains undetermined.

Oliver Glass, Ricardo Henao, Keyur Patel, Cynthia D. Guy, Hans J. Gruss, Wing‐Kin Syn, Cynthia A. Moylan, Robert Streilein, Russell Hall, Anna Mae Diehl, Manal F. Abdelmalek – 21 September 2018 – The severity of hepatic fibrosis is the primary predictor of liver‐related morbidity and mortality in patients with nonalcoholic fatty liver disease (NAFLD). Unfortunately, noninvasive serum biomarkers for NAFLD‐associated fibrosis are limited. We analyzed baseline serum samples for 24 cytokines of 97 patients with biopsy‐proven NAFLD.

Aya Ugamura, Po‐sung Chu, Nobuhiro Nakamoto, Nobuhito Taniki, Keisuke Ojiro, Taizo Hibi, Masahiro Shinoda, Hideaki Obara, Yohei Masugi, Akihiro Yamaguchi, Shunsuke Shiba, Rei Morikawa, Shingo Usui, Hirotoshi Ebinuma, Yuko Kitagawa, Hidetsugu Saito, Takanori Kanai – 21 September 2018 – A prognostic system for acute liver failure (ALF) with a higher predictive value is urgently needed. The role of extracellular matrix (ECM) remodeling in ALF has not been fully elucidated.

Virginia Hernández‐Gea, Juan Carlos Garcia‐Pagan – 21 September 2018

Patrick H. Y. Chung, Kelvin K. C. Ng, Tiffany C. L. Wong, Sui Ling Sin, Chung Mau Lo – 21 September 2018

Janghyun Kim, Bora Lee, Dae‐Hwan Kim, Jae Gwang Yeon, Jeongkyung Lee, Younjung Park, Yuna Lee, Soo‐Kyung Lee, Seunghee Lee, Jae W. Lee – 19 September 2018 – Regulation of the protein stability of epigenetic regulators remains ill‐defined despite its potential applicability in epigenetic therapies. The histone H3‐lysine 4‐methyltransferase MLL4 is an epigenetic transcriptional coactivator that directs overnutrition‐induced obesity and fatty liver formation, and Mll4+/‐ mice are resistant to both.

Charlotte E. Costentin, Yanik J. Bababekov, Andrew X. Zhu, Heidi Yeh – 19 September 2018 – Liver transplantation (LT) is considered the optimal treatment for hepatocellular carcinoma (HCC) because it removes tumor as well as the underlying cirrhotic liver. Because of a global organ shortage, LT for patients with HCC is limited to patients with expected survival comparable to that of nonmalignant indications. Therefore, identifying patients with lower rates of HCC recurrence and higher rates of survival is critical.